^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20 inhibitor

    Related drugs:
    1d
    GLO-PACT: Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, American University of Beirut Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Columvi (glofitamab-gxbm)
    1d
    Celestimo: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (clinicaltrials.gov)
    P3, N=478, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2026 --> May 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • Lunsumio (mosunetuzumab-axgb)
    1d
    CHIMES: Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab (clinicaltrials.gov)
    P4, N=179, Completed, Genentech, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Ocrevus (ocrelizumab)
    2d
    BRAWM: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
    2d
    REDUCE-PMR-2: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse (clinicaltrials.gov)
    P3, N=174, Active, not recruiting, Sint Maartenskliniek | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    2d
    Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL. (PubMed, Blood Rev)
    Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq)
    3d
    People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Northwestern University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ocrevus (ocrelizumab)
    3d
    REDUCE-PMR-1: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (clinicaltrials.gov)
    P3, N=114, Completed, Sint Maartenskliniek | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    3d
    An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P3, N=1100, Active, not recruiting, TG Therapeutics, Inc. | Trial completion date: Feb 2030 --> May 2032 | Trial primary completion date: Feb 2030 --> May 2032
    Trial completion date • Trial primary completion date
    |
    Briumvi (ublituximab-xiiy)
    3d
    ENHANCE: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (clinicaltrials.gov)
    P3, N=800, Recruiting, TG Therapeutics, Inc. | Trial completion date: Sep 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Briumvi (ublituximab-xiiy)
    3d
    GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=182, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2027 --> Mar 2028 | Trial primary completion date: Feb 2027 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    3d
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=240, Not yet recruiting, TG Therapeutics, Inc. | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Briumvi (ublituximab-xiiy) • fingolimod